ProStrakan offers patch to prevent nausea and vomiting

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Sancuso (granisetron transdermal system) is now available by prescription in the U.S. for patients with chemotherapyinduced nausea and vomiting. The patch continuously releases granisetron into the bloodstream for up to five consecutive days.

Sancuso (granisetron transdermal system) is now available by prescription in the U.S. for patients with chemotherapyinduced nausea and vomiting. The patch continuously releases granisetron into the bloodstream for up to five consecutive days.

The most common adverse reaction is constipation. No clinically relevant drug interactions have been reported in studies with Sancuso, according to the company.

Aranesp/IV iron aids chemo-induced anemia

Adding iron intravenously to darbepoetin alfa elicits a better response to chemotherapy-induced anemia than when darbepoetin alfa is taken alone, according to the results of a phase II trial presented at ESMO 2008.

Baltimore-based hematologist  Michael Auerbach, MD, and colleagues studied 238 patients with lung, gastrointestinal, breast, and other tumor types. Two doses of darbepoetin alfa (Aranesp) were compared: 500 mcg vs 300 mcg every three weeks along with IV iron or no IV iron. Target hemoglobin was at least 11 g/dL.

The researchers found 78% of 118 patients given 500 mcg of darbepoetin and 75% of 112 patients given 300 mcg reached this goal, as did 82% of 110 patients given IV iron versus 72% of 117 patients who did not receive IV iron. However, more research is needed to determine safety, commented Matti S. Aapro, MD, of the Institut Multidisciplinaire d’Oncologie in Genolier, Switzerland.

Recent Videos
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content